Loading…
Aire-Master of America, Inc. received an FDA Warning Letter in May 2022 regarding adulterated drug products manufactured in violation of Current Good Manufacturing Practice (CGMP) standards. Based on the limited metadata available, the company appears to have failed to maintain adequate manufacturing controls or quality systems for finished pharmaceuticals. The warning was issued by the FDA's Division of Pharmaceutical Quality Operations III, indicating the agency identified significant compliance gaps in the company's pharmaceutical manufacturing operations.